Core Viewpoint - The company has released promising results from recent studies on the efficacy of its traditional Chinese medicine, Pian Zai Huang, in treating COVID-19 and herpes simplex virus (HSV) infections, indicating significant survival rates and clinical benefits [1][2][3][4]. Group 1: COVID-19 Research - In animal experiments, the low-dose group of Pian Zai Huang showed an 83% survival rate among hamsters infected with COVID-19, compared to a 0% survival rate in the control group [2]. - The study demonstrated that hamsters treated with Pian Zai Huang had significantly reduced lung hemorrhage and lesions compared to untreated hamsters [2]. - Previous clinical observations published in the journal "Frontiers in Medicine" also support the efficacy of Pian Zai Huang in COVID-19 recovery [2]. Group 2: Herpes Virus Research - Animal studies indicated that medium-dose Pian Zai Huang could extend the survival of mice infected with HSV-1, with some mice achieving full recovery [2]. - A clinical study led by Guangdong Provincial Hospital showed that Pian Zai Huang significantly alleviated pain intensity and improved immune function in patients with shingles, particularly in older adults [3]. Group 3: Broader Clinical Applications - The company is actively exploring the clinical value of Pian Zai Huang beyond liver diseases, with recent studies indicating its potential in treating chronic hepatitis B and improving liver fibrosis [4]. - A prospective randomized controlled trial involving 144 chronic hepatitis B patients showed that Pian Zai Huang combined with entecavir significantly improved liver fibrosis stages [4]. - The company plans to advance 11 clinical research projects and 23 pharmacological studies in 2024, further expanding the applications of Pian Zai Huang [5].